Literature DB >> 29549020

The CCL5/CCR5 Chemotactic Pathway Promotes Perineural Invasion in Salivary Adenoid Cystic Carcinoma.

Tao Gao1, Zhiyuan Shen2, Chao Ma3, Yun Li3, Xiangfeng Kang4, Moyi Sun5.   

Abstract

PURPOSE: Perineural invasion (PNI) is a hallmark of salivary adenoid cystic carcinoma (SACC) and represents an important risk factor for local recurrence and poor survival. However, the mechanism of PNI has yet to be explored. We sought to examine the CCL5-CCR5 ligand-receptor interaction between nerves and SACC cells.
MATERIALS AND METHODS: CCL5/CCR5 expression was determined by immunohistochemistry in SACC tissue specimens. The correlations between CCL5/CCR5 expression and clinicopathologic features were investigated. Dorsal root ganglia (DRG) and SACC cells cocultured in vitro were used to evaluate the effects of CCL5/CCR5 on PNI progression and pathogenesis.
RESULTS: CCR5 expression was significantly elevated in SACC tissues and associated with distant metastasis, PNI, and TNM grade (P < .05). DRG and SACC cells cocultured in vitro showed that the activation of the CCL5/CCR5 axis significantly increased SACC cell invasion and promoted the outgrowth of the DRG. SACC cell lines expressing CCR5 migrated in response to CCL5 derived from DRG, eventually leading to PNI. More importantly, further study showed that blocking of CCL5 or CCR5 effectively inhibited the invasive capacity and PNI activity of SACC cells (P < .05).
CONCLUSIONS: Our results suggest a pivotal role of CCL5/CCR5 axis in tumor-nerve interactions during PNI of SACC. The CCL5/CCR5 pathway might prove to be an attractive new target for the treatment of SACC with PNI.
Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29549020     DOI: 10.1016/j.joms.2018.02.009

Source DB:  PubMed          Journal:  J Oral Maxillofac Surg        ISSN: 0278-2391            Impact factor:   1.895


  6 in total

1.  SNAIL Transctiption factor in prostate cancer cells promotes neurite outgrowth.

Authors:  Gabrielle Edwards; Taaliah Campbell; Veronica Henderson; Alira Danaher; Daqing Wu; Rekha Srinivasan; Khosrow Rezvani; Valerie A Odero-Marah
Journal:  Biochimie       Date:  2020-10-24       Impact factor: 4.079

2.  Sympathetic innervation contributes to perineural invasion of salivary adenoid cystic carcinoma via the β2-adrenergic receptor.

Authors:  Chao Ma; Tao Gao; Jun Ju; Yi Zhang; Qianwei Ni; Yun Li; Zhenyan Zhao; Juan Chai; Xiangming Yang; Moyi Sun
Journal:  Onco Targets Ther       Date:  2019-02-21       Impact factor: 4.147

3.  CCL3-CCR5 axis contributes to progression of esophageal squamous cell carcinoma by promoting cell migration and invasion via Akt and ERK pathways.

Authors:  Takayuki Kodama; Yu-Ichiro Koma; Noriaki Arai; Aya Kido; Naoki Urakawa; Mari Nishio; Manabu Shigeoka; Hiroshi Yokozaki
Journal:  Lab Invest       Date:  2020-05-26       Impact factor: 5.662

Review 4.  CCL5/CCR5 axis in human diseases and related treatments.

Authors:  Zhen Zeng; Tianxia Lan; Yuquan Wei; Xiawei Wei
Journal:  Genes Dis       Date:  2021-08-26

5.  Targeting neurons in the tumor microenvironment with bupivacaine nanoparticles reduces breast cancer progression and metastases.

Authors:  Maya Kaduri; Mor Sela; Shaked Kagan; Maria Poley; Hanan Abumanhal-Masarweh; Patricia Mora-Raimundo; Alberto Ouro; Nitsan Dahan; Dov Hershkovitz; Jeny Shklover; Janna Shainsky-Roitman; Yosef Buganim; Avi Schroeder
Journal:  Sci Adv       Date:  2021-10-06       Impact factor: 14.136

Review 6.  Biological Rationale and Clinical Evidence of Carbon Ion Radiation Therapy for Adenoid Cystic Carcinoma: A Narrative Review.

Authors:  Pierre Loap; Barbara Vischioni; Maria Bonora; Rossana Ingargiola; Sara Ronchi; Viviana Vitolo; Amelia Barcellini; Lucia Goanta; Ludovic De Marzi; Remi Dendale; Roberto Pacelli; Laura Locati; Valentin Calugaru; Hamid Mammar; Stefano Cavalieri; Youlia Kirova; Ester Orlandi
Journal:  Front Oncol       Date:  2021-11-30       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.